Robert Froman Williamson, III
About Robert Froman Williamson, III
Robert Froman Williamson, III is an independent director of Perspective Therapeutics, Inc. (CATX), serving since February 5, 2023. He is 59 years old and holds a BA in economics from Pomona College and an MBA from Stanford University . Williamson is described as a qualified financial expert with deep operating and financing experience across biotech, having chaired both the Audit and Compensation Committees at CATX .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Triumvira Immunologicals (private) | Acting CEO, President, COO, Director | Since Sep 2022 | Senior operating leadership |
| SyntheX (private) | Senior Adviser | Since Mar 2022 | Strategic advisory |
| OncoMyx | CBO/CFO | Feb–Sep 2022 | Corporate, finance leadership |
| BioTheryX | CEO | 2020–2021 | Raised $100M crossover, IPO prep |
| PharmAkea | CEO | 2013–2019 | Celgene-backed programs; later acquired |
| ATXCo | CEO | 2019 | Later acquired |
| Strategic Enzyme Applications | Executive Chairman & Founder | n/a | Company builder |
| Arriva Pharmaceuticals | CEO | n/a | Executive leadership |
| Eos Biotechnology | President & COO | n/a | Sold to Protein Design Labs |
| DoubleTwist, Inc. | COO | n/a | Acquired by Merck & Hitachi |
| Pharmasset, Inc. | Early Director | Pre‑2011 | Helped grow to $11B sale to Gilead |
| The Boston Consulting Group | Partner | n/a | Strategy expertise |
| Federal Reserve Board | Research Assistant | n/a | Analytical foundation |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| University of Miami – Coulter Oversight Board | Board Member | n/a | Academic/innovation oversight |
Board Governance
- Independence: Determined independent under NYSE American standards; serves on Audit, Compensation, and Nominations & Corporate Governance Committees .
- Committee assignments (2024): Compensation Committee Chair; Audit Committee Member; Nominations & Corporate Governance Member. Board met 7 times; Audit 4; Compensation 7; Nominations 2 .
- Attendance: Each current Board member attended at least 75% of Board and committee meetings in FY2024; all directors attended the most recent annual meeting .
- Executive sessions: Independent directors meet at least annually per NYSE American standards .
- Election results (2025): Williamson received 41,915,458 For; 10,652,577 Withheld; 8,282,256 broker non-votes, re‑elected through the 2026 annual meeting .
Fixed Compensation
| Component | Policy/Amount | Williamson 2024 | Notes |
|---|---|---|---|
| Annual cash retainer | $60,000 policy | $60,000 | Non‑employee director |
| Committee chair fee | $15,000 policy (per chair) | $15,000 | Compensation Committee Chair |
| Board Chair premium | $30,000 policy | n/a | Applies to Board Chair (not Williamson) |
| Total cash | — | $75,000 | Reported fees earned or paid in cash |
Performance Compensation
| Equity Grant | Grant Size | Vesting | Term | 2024 Grant Date Fair Value | Notes |
|---|---|---|---|---|---|
| Non‑employee director stock options (2024 program) | 23,000 options | 100% vest on first anniversary | 10 years | $192,540 | Exercise price at grant-date close; standard plan terms |
No director PSUs/RSUs or performance metric‑linked equity disclosed for directors; director equity is time‑vested options under the 2020 Equity Incentive Plan .
Comp committee infrastructure and controls:
- Use of independent compensation consultants: Anderson Pay Advisors (2023), Aon (2024) engaged to review compensation programs .
- Peer group (May 2024): 21 oncology/biotech peers (e.g., ALXO, CGON, RELY, FUSN, KURA). Used to benchmark executive long‑term incentives; target percentile not disclosed .
- Option practices: No option repricing or material modifications in 2023 or 2024 .
- Clawback: Incentive Compensation Recovery Policy for restatements per SEC/NYSEA rules .
Other Directorships & Interlocks
| Company | Public/Private | Role | Potential Interlock/Conflict |
|---|---|---|---|
| Pharmasset, Inc. (historical) | Public (acquired by Gilead 2011) | Early Director | Historical; no current CATX conflict disclosed |
| Triumvira Immunologicals | Private | Acting CEO/President/COO/Director | No CATX related‑party disclosure |
| SyntheX | Private | Senior Adviser | No CATX related‑party disclosure |
Expertise & Qualifications
- Financial expertise: Qualified financial expert; serves on Audit Committee .
- Sector expertise: 20+ years building biotech/technology firms; leadership across protein degradation, immuno‑oncology, virology and genomics .
- Education: BA economics (Pomona), MBA (Stanford) .
Equity Ownership
| Category | Amount | Breakdown | Percent of Class |
|---|---|---|---|
| Common shares owned (as of Apr 2, 2025) | 109,348 | 108,982 direct; 366 in trust | <1% |
| Stock options exercisable within 60 days | 81,255 | — | n/a |
| Warrants | — | — | — |
Insider Trading Policy prohibits hedging, short sales, pledging, margin accounts; applies to directors and covered persons .
Governance Assessment
- Committee leadership and independence: Williamson chairs Compensation and serves on Audit and Nominations; Board affirms independence for these roles, supporting robust oversight of pay and financial reporting .
- Attendance and engagement: Board‑wide attendance met the 75% threshold, and all directors attended the annual meeting, supporting baseline engagement expectations .
- Ownership and alignment: Holds 109,348 shares and 81,255 options exercisable within 60 days; director equity granted annually (time‑vested options) aligns with shareholder value creation, though not tied to explicit performance metrics .
- Controls and policies: Clawback policy in place; hedging/pledging prohibited; no option repricing in recent years—positive governance signals .
- Shareholder support signals: 2025 re‑election received 41.9M For vs. 10.7M Withheld; say‑on‑pay passed with 38.7M For vs. 13.7M Against—both indicative of acceptable, though not unanimous, investor support .
- RED FLAGS:
- Section 16 timeliness (2023): One late Form 3 and one late Form 4 for Williamson; isolated filing timeliness issue noted by the company .
- Related‑party exposure context: Lantheus Alpha holds ~15.77% with board observer/information and participation rights; substantial holder influence warrants ongoing monitoring, though no Williamson‑specific related‑party transactions are disclosed .
Overall, Williamson’s independent status, committee leadership, and financial expertise support board effectiveness. Monitoring is advised around large‑holder dynamics (Lantheus rights) and continued clarity on director equity practices (time‑vesting vs. performance‑linkage) .